An antibody with three targets
LBL-051 targets BCMA, CD19 and CD3 to recruit T cells against B-cell and plasma-cell populations implicated in autoimmune disease. Oblenio is developing the programme for patients whose disease has resisted existing treatments. At the announcement, the company was preparing to move from preclinical work into human studies.
Funding the first clinical programme
The proceeds will support initial clinical development, including the planned first-in-human proof-of-concept study.
Where the funding goes
- Advance LBL-051 initial clinical development
- Initiate the first-in-human proof-of-concept study